NASDAQ$BMEA
Biomea Fusion Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported financial results for the first quarter 2021.
Biomea Fusion reported a net loss attributable to common stockholders of $5.9 million for the first quarter of 2021, compared to a net loss of $0.4 million for the same period in 2020. As of March 31, 2021, the Company had cash, cash equivalents, restricted cash, and investments of $57.5 million.
- Received $167 million in aggregate gross proceeds in April from initial public offering
- Advancing lead oncology program BMF-219, a small molecule irreversible menin inhibitor, toward IND filing in second half of 2021
- Mick Hitchcock, Ph.D., former senior advisor to Gilead joined the Board of Directors
- Completed initial public offering (“IPO”) in April. The Company’s common stock commenced trading on the Nasdaq Global Select Market under the ticker symbol “BMEA” on April 16, 2021.
Headline financials
Revenue & EPS history
Biomea Fusion · Revenue · Quarterly
$1.07B
Forward guidance
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
+5.2%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+3.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+109.7%
Q4 2022
Best reaction
-16.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +15.3% | -13.5% | -23.7% | |
| Q3 2025 | -0.7% | -4.3% | -21.0% | |
| Q2 2025 | +0.6% | -3.2% | +21.5% | |
| Q1 2025 | -1.3% | -4.6% | +73.0% | |
| Q4 2024 | +1.2% | -7.8% | -8.7% | |
| Q3 2024 | -16.7% | -27.2% | -43.4% | |
| Q1 2024 | +6.7% | +3.7% | -9.1% | |
| Q4 2023 | -14.4% | -14.8% | -22.6% | |
| Q3 2023 | -6.8% | -7.9% | +16.3% | |
| Q2 2023 | -2.4% | -9.3% | -22.2% | |
| Q1 2023 | -3.3% | +2.6% | +12.5% | |
| Q4 2022 | +109.7% | +101.0% | +84.6% | |
| Q3 2022 | -15.6% | -29.4% | -43.3% | |
| Q2 2022 | +3.3% | +11.8% | +8.5% | |
| Q1 2022 | +35.2% | +69.4% | +127.2% | |
| Q4 2021 | -13.8% | -7.7% | -36.2% | |
| Q3 2021 | +7.6% | +2.0% | -7.9% | |
| Q2 2021 | -0.6% | -11.0% | -3.4% | |
| Q1 2021 | -0.3% | +7.9% | -21.4% | |
| Q4 2020 | -0.3% | +7.9% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro